FeesSafety
Pluang+

NKGen Biotech reports sustained cognitive improvement in Alzheimer's patient after 24 months of troculeucel treatment

Company Fundamentals
16 Nov 2026, 20:05 WIB
GlobeNewsWire
View Source
Bullish
NKGen Biotech reports sustained cognitive improvement in Alzheimer's patient after 24 months of troculeucel treatment

NKGen Biotech presented long-term clinical observations from a patient with moderate Alzheimer's disease treated with their investigational NK cell therapy, troculeucel. The patient's cognitive score improved rapidly from moderate to mild Alzheimer's within three months and remained stable over 24 months, including a 12-month open-label extension. No treatment-related adverse events were reported. These findings, while from a single patient, support further evaluation of troculeucel in ongoing Phase 2a trials, with interim results expected in late 2027.

NKGen Biotech's Alzheimer's treatment trial data provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 17, 2026 00:22 WIB: of 150 priced health-sector US stocks, 56 rose and 94 fell today. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) down 12.70% at USD 8.39 with a typical hold time of 9 days, FLNA (Cassava Sciences Inc) up 11.20% at USD 0.47 with a typical hold time of 39 days, and ALMS (Alumis Inc. Common Stock) down 9.11% at USD 5.09 with a typical hold time of 19 days.

More News

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

European Commission approves RASONQUE for metastatic pancreatic cancer treatment

The European Commission has approved RASONQUE (daraxonrasib), the first broad RAS-targeted oral medicine for adults with metastatic pancreatic adenocarcinoma who have had prior systemic therapy. This approval covers patients with or without identifie...

Market News
Bullish
58 minutes ago
SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE acquires Duflex to boost industrial automation and robotics in the Netherlands.

SPIE, a European leader in multi-technical services, has acquired Dutch company Duflex B.V. to enhance its industrial automation, machine building, and robotics capabilities. Duflex, with 26 employees and €8 million revenue in 2025, specializes in ta...

Company Fundamentals
Bullish
1 hour ago
Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 from Nov 9-13, 2026

Rexel Développement SAS disclosed that it repurchased a total of 3,878 of its own shares between November 9 and November 13, 2026. The average purchase price during this period was approximately €34.67 per share. This buyback is part of an authorized...

Company Fundamentals
Neutral
1 hour ago
Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel repurchases 3,878 own shares at an average price of €34.67 in early November 2026

Rexel Développement SAS announced it bought back a total of 3,878 of its own shares between November 9 and 13, 2026, at an average price of €34.67 per share. This share repurchase is part of the authorization granted by its shareholders to operate on...

Company Fundamentals
Neutral
1 hour ago
SPIE acquires Duflex B.V. to boost industrial automation and robotics expertise in the Netherlands.

SPIE acquires Duflex B.V. to boost industrial automation and robotics expertise in the Netherlands.

SPIE, a leading European multi-technical services company, has acquired Duflex B.V., a Dutch firm specializing in industrial automation, machine construction, and robotics. This acquisition strengthens SPIE's capabilities in the industrial services v...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App